SCHEMBL7857656

SCHEMBL7857656

COc1ccc(C(=O)Nc2ccc(C(=O)O)cc2)cc1NCc1cccs1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.55
POLB P06746 2/20 0.55
MEN1 O00255 6/20 0.53
KMT2A Q03164 6/20 0.53
KDM4E B2RXH2 3/20 0.53
THRB P10828 2/20 0.53
HPGD P15428 1/20 0.53
PKM P14618 1/20 0.52
HDAC1 Q13547 1/20 0.51
HDAC8 Q9BY41 1/20 0.51
HDAC6 Q9UBN7 1/20 0.51
LMNA P02545 1/20 0.51
L3MBTL1 Q9Y468 3/20 0.49
ALDH1A1 P00352 2/20 0.49
RECQL P46063 1/20 0.49
BLM P54132 1/20 0.49
CTDSP1 Q9GZU7 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
NPSR1 Q6W5P4 1/20 0.48
RXFP1 Q9HBX9 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7152820 0.94 HDAC8 (0.56) MAPTPOLBMEN1KMT2AKDM4E
SCHEMBL7147183 0.91 MAPT (0.54) MAPTPOLBMEN1KMT2AKDM4E
SCHEMBL7153179 0.88 RAB9A (0.57) MAPTPOLBMEN1KMT2AKDM4E
SCHEMBL7154583 0.87 MAPT (0.55) MAPTPOLBMEN1KMT2AKDM4E
SCHEMBL7155890 0.87 MAPT (0.50) MAPTPOLBMEN1KMT2AKDM4E
SCHEMBL7150679 0.85 KMT2A (0.50) MAPTPOLBMEN1KMT2AKDM4E
SCHEMBL7154797 0.85 MAPT (0.58) MAPTPOLBMEN1KMT2AKDM4E
SCHEMBL7151899 0.84 LMNA (0.62) POLBMEN1KMT2ALMNAL3MBTL1
SCHEMBL7149497 0.82 MAPK1 (0.58) MAPTPOLBMEN1KMT2ATHRB
SCHEMBL7147213 0.81 HDAC8 (0.69) MEN1KMT2APKMHDAC1HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010031874-A1 Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis CONNOR DAVID THOMAS (US) 2001-10-18 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010031874-A1 Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis TPMT, CTH, CBS MAPT 3879/4885POLB 2441/4885MEN1 3193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.